Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Clinical Characteristics of Patients Requiring a Second Dose of Radioactive Iodine for the Treatment of Graves’ Disease
source: Thyroid
year: 2018
authors: O’Keeffe DT, Abdullah A, Bell M
summary/abstract:Graves’ disease is an autoimmune condition affecting the thyroid gland and is a common cause of hyperthyroidism. The main treatment goals are the reduction in thyroid hormone overproduction either with antithyroid drugs (ATD), surgery or radioactive iodine (RAI) therapy.
The aim of RAI (I-131) therapy is to treat hyperthyroidism by destroying sufficient thyroid tissue to render the patient either euthyroid or hypothyroid. The objective of this work was to examine the outcomes of RAI treatment for Graves’ disease in a large patient cohort over a two year period in a West of Ireland tertiary referral academic medical centre.
In particular, we focused on the characteristics of those patients requiring a second RAI administration. Institutional Review Board approval was obtained for this study and thereafter the clinical records of all the patients who underwent RAI treatment were examined. The data demonstrated that 150 patients underwent RAI treatment from Jan 2014 to Dec 2015.
organization: University Hospital Galway, IrelandDOI: 10.1089/thy.2018.29065.abstracts
read more
myBinderRelated Content
-
Oftalmopatía de Graves u Orbitopatía de Graves¿Qué Es La Oftalmopatía De Graves? L...
-
Victor Maurice Elner, MD, PhDVictor Maurice Elner is a Professor of o...
-
Thyroid Eye Disease and the Role of the TED SpecialistNot all people with thyroid disease have...
-
Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves’ OphthalmopathyThe purpose of the current study is to c...
-
Teprotumumab Significantly Improves Proptosis in Thyroid eye DiseasePatients with thyroid eye disease treate...
-
Thyroid Surgery for Graves’ Disease and Graves’ OphthalmopathyBackground: Graves' disease is an autoi...
-
U.S. Physician Survey Illustrates the Devastating Impact of Thyroid Eye Disease on Patient Quality of LifeHorizon Therapeutics plc today announced...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google